VKTX's Quality Score fell 1 point on Tue, Nov 10, to -1. It closed away from its high of the day.
Follow VKTX's trial news. Pro members can get an alert when Viking Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 6% on Oct 29, and still 14% over its Oct 28 close.
Down 23% over the year to Nov 9 while the S&P 500 rose 12%; up 6% on Oct 29.
1 reason, from its filings, with the timeline, for Pro members.
| Since its 2024 high | Down 69% |
| Latest filing | 10-Q, Oct 29 |
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
6 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +2.8% on average, higher 2 of 4 times.
About 8 quarters
CEO Brian Lian sold 148,517 shares on Jul 29. 7 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
VKTX is #154 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 154 |
Net income over four quarters: VKTX -$627M, MBX -$145M, MDGL -$155M, GPCR -$294M.
Expected to report Wed Feb 10, after the close (in 92 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.55 a share, from $0.81.
“The increase in net loss for the three months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025.”
VKTX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to increased expenses related to planned and ongoing clinical studies, manufacturing for the company's drug candidates, stock-based compensation, salaries and benefits and third-party consultants, partially offset by decreased expenses related to preclinical studies.”
From its results filing (SEC filing · Oct 28)
Its share count grew 14% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | -3.9% | +5.9% | +10.3% |
| Jul 29, 2026 | +0.3% | -1.0% | +0.2% |
| Apr 29, 2026 | -2.7% | -0.5% | +3.0% |
Sales fell every year from 2018 to 2025, to $0. It lost money in each of the eight years.
RSI 53.4, MACD above signal, below both averages. Not scored.
3 insiders sold $6.3M across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VKTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
“The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
VKTX scores -1 today, which Breakaway calls Poor. It is #154 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 6% on Oct 29, and still 14% over its Oct 28 close. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VKTX scores -1 today, which Breakaway calls Poor (below zero). That is #154 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VKTX's -1.
3 insiders sold $6.3M across 3 filings in the last 6 months. No open-market buys on record. The newest is Brian Lian, President & CEO, who sold $4.9M on Jul 29. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.